Clinical Trials Logo

Clinical Trial Summary

Galantamine is an experimental drug being evaluated in the United States for the treatment of Alzheimer's disease. Results from previous clinical trials suggest that galantamine may improve cognitive performance in individuals with Alzheimer's disease. It is not a cure for Alzheimer's disease. Nerve cells in the brain responsible for memory and cognitive function communicate using a chemical called acetylcholine. Research has shown that deterioration of cells that produce acetylcholine in the brain affects thought processes. Galantamine is thought to work in two ways to increase the amount of acetylcholine available in the brain. It inhibits an enzyme that breaks down acetylcholine and it also stimulates the nicotinic receptors in the brain to release more acetylcholine.


Clinical Trial Description

After a 1-month single-blind run in phase, 910 subjects will be titrated, over a period of up to 8 weeks, to target doses of either: 0 (placebo); 24 mg/day galantamine; 16 mg/day galantamine; or 8 mg/day galantamine, in a 2:2:2:1 randomization ratio. Double-blind treatment will continue for a total of 5 months. The change from baseline in ADAS-cog and CIVIC-plus scores at Month 5 will be the primary efficacy endpoints. Tolerability will be evaluated based on adverse event reports, laboratory values, ECG, and vital signs with particular focus on the adverse event rates in the slower titration schedule for 24 mg/day. Efficacy of 24 mg/day and 16 mg/day galantamine will be compared with that of placebo. Information on the dose response relationship of galantamine will be evaluated. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00000172
Study type Interventional
Source National Institute on Aging (NIA)
Contact
Status Completed
Phase Phase 3

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03430648 - Is Tau Protein Linked to Mobility Function? N/A
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Not yet recruiting NCT03208491 - AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders N/A
Not yet recruiting NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Not yet recruiting NCT03654911 - Sustainable Method for Alzheimer's Prediction
Not yet recruiting NCT03638323 - Age-related Hearing Loss and Lexical Disorders
Recruiting NCT03056495 - Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease Phase 1
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT03095417 - Improving the Recovery and Outcome Every Day After the ICU N/A
Not yet recruiting NCT03256539 - Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease N/A
Recruiting NCT03670615 - Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia N/A
Not yet recruiting NCT03514875 - Effects of Mitochondrial-targeted Antioxidant on Alzheimer's Disease N/A
Not yet recruiting NCT03634007 - Gene Therapy for APOE4 Homozygote of Alzheimer's Disease Phase 1
Not yet recruiting NCT03116126 - Noradrenergic Add-on Therapy With Guanfacine Phase 3
Recruiting NCT02835716 - Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO N/A
Completed NCT02253732 - Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs N/A
Recruiting NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Active, not recruiting NCT02172612 - A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly N/A
Completed NCT03034746 - Impact of Physical Activity on Successful Aging N/A
Completed NCT01823666 - Predicting the Conversion From Mild Cognitive Impairment to Dementia N/A